BRPI0809715A2 - "composto, método de tratamento de um distúrbio relacionado com a angiogênese,método de inibição da atividade de receptor de domínio de inserto de quinase, método de inibição de angiogênese e método de tratamento de degeneração macular" - Google Patents
"composto, método de tratamento de um distúrbio relacionado com a angiogênese,método de inibição da atividade de receptor de domínio de inserto de quinase, método de inibição de angiogênese e método de tratamento de degeneração macular" Download PDFInfo
- Publication number
- BRPI0809715A2 BRPI0809715A2 BRPI0809715-1A BRPI0809715A BRPI0809715A2 BR PI0809715 A2 BRPI0809715 A2 BR PI0809715A2 BR PI0809715 A BRPI0809715 A BR PI0809715A BR PI0809715 A2 BRPI0809715 A2 BR PI0809715A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- angiogenesis
- compound
- macular degeneration
- related disorder
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 208000002780 macular degeneration Diseases 0.000 title abstract 2
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 title 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91192107P | 2007-04-16 | 2007-04-16 | |
| PCT/US2008/060366 WO2008128231A1 (en) | 2007-04-16 | 2008-04-15 | Pyrimidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0809715A2 true BRPI0809715A2 (pt) | 2019-11-05 |
Family
ID=39854302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0809715-1A BRPI0809715A2 (pt) | 2007-04-16 | 2008-04-15 | "composto, método de tratamento de um distúrbio relacionado com a angiogênese,método de inibição da atividade de receptor de domínio de inserto de quinase, método de inibição de angiogênese e método de tratamento de degeneração macular" |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8349859B2 (enExample) |
| EP (1) | EP2154967B9 (enExample) |
| JP (1) | JP5635398B2 (enExample) |
| KR (1) | KR101424847B1 (enExample) |
| BR (1) | BRPI0809715A2 (enExample) |
| CA (1) | CA2684470C (enExample) |
| DK (1) | DK2154967T5 (enExample) |
| ES (1) | ES2465673T3 (enExample) |
| HR (1) | HRP20140377T2 (enExample) |
| MX (1) | MX2009011199A (enExample) |
| NZ (1) | NZ580671A (enExample) |
| PL (1) | PL2154967T3 (enExample) |
| PT (1) | PT2154967E (enExample) |
| RU (1) | RU2455994C2 (enExample) |
| SI (1) | SI2154967T1 (enExample) |
| TW (1) | TWI484960B (enExample) |
| WO (1) | WO2008128231A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| TW201024281A (en) | 2008-11-24 | 2010-07-01 | Boehringer Ingelheim Int | New compounds |
| AR074210A1 (es) * | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina como inhibidores de ptk2-quinasa |
| JP2012197231A (ja) * | 2009-08-06 | 2012-10-18 | Oncotherapy Science Ltd | Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体 |
| US8466155B2 (en) * | 2009-10-02 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Pyrimidines |
| CN102070618B (zh) * | 2009-11-23 | 2013-08-21 | 和记黄埔医药（上海）有限公司 | 一种化合物及其晶体 |
| US8927547B2 (en) | 2010-05-21 | 2015-01-06 | Noviga Research Ab | Pyrimidine derivatives |
| EP2395001A1 (en) | 2010-05-21 | 2011-12-14 | Chemilia AB | Novel pyrimidine derivatives |
| EP2433636A1 (en) * | 2010-09-27 | 2012-03-28 | Medizinische Universität Wien | Treatment of Malignant Diseases |
| US8785467B2 (en) | 2010-09-30 | 2014-07-22 | Merck Sharp & Dohme Corp. | Alkoxy pyrimidine PDE10 inhibitors |
| AU2012230229A1 (en) | 2011-03-24 | 2013-10-10 | Noviga Research Ab | Novel pyrimidine derivatives |
| EP2502924A1 (en) | 2011-03-24 | 2012-09-26 | Chemilia AB | Novel pyrimidine derivatives |
| WO2013054351A1 (en) * | 2011-08-08 | 2013-04-18 | Cadila Healthcare Limited | Heterocyclic compounds |
| EP2711364A1 (en) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer |
| EP2711365A1 (en) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer |
| BR112015010109A2 (pt) * | 2012-11-05 | 2017-07-11 | Nant Holdings Ip Llc | derivados de indol-5-ol substituídos e suas aplicações terapêuticas |
| WO2014145403A1 (en) * | 2013-03-15 | 2014-09-18 | Nantbio, Inc. | Substituted indol-5-ol derivatives and their therapeutic applications |
| CN105601573B (zh) * | 2014-11-24 | 2021-07-02 | 中国科学院上海药物研究所 | 2-氨基嘧啶类化合物及其药物组合物和应用 |
| WO2016137506A1 (en) * | 2015-02-27 | 2016-09-01 | Nantbioscience, Inc. | Pyrimidine derivatives as kinase inhibitors and their therapeutical applications |
| US10981899B2 (en) | 2016-04-28 | 2021-04-20 | Cornell University | Inhibitors of soluble adenylyl cyclase |
| WO2020253862A1 (zh) * | 2019-06-21 | 2020-12-24 | 上海翰森生物医药科技有限公司 | 含氮芳基磷氧化物类衍生物、其制备方法和应用 |
| CN111004221B (zh) * | 2019-12-13 | 2021-02-02 | 长治学院 | 一种嘧啶/苯并咪唑杂合物、制备方法及医药用途 |
| US20240166635A1 (en) * | 2020-11-27 | 2024-05-23 | Anrui Biomedical Technology (Guangzhou) Co.,Ltd. | Aminoheteroaryl kinase inhibitors |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| HRP970371A2 (en) * | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
| US6235741B1 (en) * | 1997-05-30 | 2001-05-22 | Merck & Co., Inc. | Angiogenesis inhibitors |
| PL199802B1 (pl) | 1999-02-10 | 2008-10-31 | Astrazeneca Ab | Pochodne chinazoliny, sposoby ich wytwarzania, ich kompozycje farmaceutyczne i ich zastosowania |
| GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9924862D0 (en) * | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
| US6943161B2 (en) * | 1999-12-28 | 2005-09-13 | Pharmacopela Drug Discovery, Inc. | Pyrimidine and triazine kinase inhibitors |
| WO2001060816A1 (en) * | 2000-02-17 | 2001-08-23 | Amgen Inc. | Kinase inhibitors |
| GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| WO2002016348A1 (en) * | 2000-08-09 | 2002-02-28 | Astrazeneca Ab | Antiangiogenic bicyclic derivatives |
| US20020137755A1 (en) | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
| KR100847169B1 (ko) * | 2000-12-21 | 2008-07-17 | 글락소 그룹 리미티드 | 혈관형성 조절제로서의 피리미딘아민 |
| WO2002070477A1 (en) * | 2001-03-01 | 2002-09-12 | Ono Pharmaceutical Co., Ltd. | 2-methylindole-4-acetic acid, process for producing the same, and process for producing intermediate therefor |
| WO2002102783A1 (en) * | 2001-06-19 | 2002-12-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| AU2003220970A1 (en) | 2002-03-01 | 2003-09-16 | Smithkline Beecham Corporation | Diamino-pyrimidines and their use as angiogenesis inhibitors |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| WO2003106416A2 (en) | 2002-06-17 | 2003-12-24 | Smithkline Beecham Corporation | Chemical process |
| IL166241A0 (en) * | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
| KR100732440B1 (ko) * | 2002-08-30 | 2007-06-27 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 질소 함유 방향환 유도체 |
| JP2006503081A (ja) | 2002-10-10 | 2006-01-26 | スミスクライン ビーチャム コーポレーション | 化学化合物 |
| CN1717396A (zh) | 2002-11-28 | 2006-01-04 | 舍林股份公司 | Chk－、Pdk－和Akt－抑制嘧啶,其制备及作为药物的用途 |
| US7531553B2 (en) | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
| US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| EP1678147B1 (en) * | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| GB0321710D0 (en) | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
| CA2538413A1 (en) * | 2003-09-18 | 2005-03-24 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
| US20050267182A1 (en) * | 2003-11-13 | 2005-12-01 | Ambit Biosciences Corporation | Urea derivatives as FLT-3 modulators |
| US7718697B2 (en) | 2003-12-17 | 2010-05-18 | Alcon, Inc. | Method for treating glaucoma comprising administering α-lipoic acid |
| MXPA06007242A (es) | 2003-12-23 | 2006-08-18 | Pfizer | Nuevos derivados de quinolina. |
| DE102004044556A1 (de) * | 2004-09-15 | 2006-03-30 | Bayer Healthcare Ag | Behandlung viraler Infektionen durch selektive Zerstörung virusinfizierter Zellen mit Stresskinase-Inhibitoren |
| TW200628463A (en) * | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | Heteroaryl compounds |
| WO2006060194A1 (en) * | 2004-11-19 | 2006-06-08 | Synta Pharmaceuticals Corp. | Pyrimidine compounds and uses thereof |
| WO2006071079A1 (en) | 2004-12-29 | 2006-07-06 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof |
| KR100735639B1 (ko) | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
| US20060247263A1 (en) * | 2005-04-19 | 2006-11-02 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| CA2604551A1 (en) * | 2005-05-03 | 2007-03-08 | Rigel Pharmaceuticals, Inc. | Jak kinase inhibitors and their uses |
| WO2006138304A2 (en) | 2005-06-14 | 2006-12-28 | Taigen Biotechnology | Pyrimidine compounds |
| WO2007035309A1 (en) * | 2005-09-15 | 2007-03-29 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
-
2008
- 2008-04-15 HR HRP20140377AT patent/HRP20140377T2/hr unknown
- 2008-04-15 JP JP2010504191A patent/JP5635398B2/ja not_active Expired - Fee Related
- 2008-04-15 ES ES08745881.6T patent/ES2465673T3/es active Active
- 2008-04-15 EP EP08745881.6A patent/EP2154967B9/en active Active
- 2008-04-15 WO PCT/US2008/060366 patent/WO2008128231A1/en not_active Ceased
- 2008-04-15 TW TW097113595A patent/TWI484960B/zh not_active IP Right Cessation
- 2008-04-15 CA CA2684470A patent/CA2684470C/en active Active
- 2008-04-15 SI SI200831203T patent/SI2154967T1/sl unknown
- 2008-04-15 PL PL08745881T patent/PL2154967T3/pl unknown
- 2008-04-15 NZ NZ580671A patent/NZ580671A/xx not_active IP Right Cessation
- 2008-04-15 BR BRPI0809715-1A patent/BRPI0809715A2/pt not_active Application Discontinuation
- 2008-04-15 DK DK08745881.6T patent/DK2154967T5/en active
- 2008-04-15 PT PT87458816T patent/PT2154967E/pt unknown
- 2008-04-15 RU RU2009141982/04A patent/RU2455994C2/ru active
- 2008-04-15 KR KR1020097023882A patent/KR101424847B1/ko not_active Expired - Fee Related
- 2008-04-15 MX MX2009011199A patent/MX2009011199A/es active IP Right Grant
- 2008-04-16 US US12/103,876 patent/US8349859B2/en not_active Expired - Fee Related
-
2012
- 2012-11-08 US US13/672,078 patent/US8901143B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008128231A1 (en) | 2008-10-23 |
| EP2154967B9 (en) | 2014-07-23 |
| EP2154967A4 (en) | 2010-05-19 |
| JP5635398B2 (ja) | 2014-12-03 |
| DK2154967T3 (da) | 2014-04-07 |
| CA2684470A1 (en) | 2008-10-23 |
| HRP20140377T1 (en) | 2014-05-23 |
| EP2154967A1 (en) | 2010-02-24 |
| AU2008240084A1 (en) | 2008-10-23 |
| US20080255172A1 (en) | 2008-10-16 |
| MX2009011199A (es) | 2010-03-17 |
| JP2010524952A (ja) | 2010-07-22 |
| US8901143B2 (en) | 2014-12-02 |
| TWI484960B (zh) | 2015-05-21 |
| EP2154967B1 (en) | 2014-03-05 |
| CA2684470C (en) | 2016-02-09 |
| ES2465673T9 (es) | 2014-11-14 |
| RU2009141982A (ru) | 2011-05-27 |
| HRP20140377T2 (hr) | 2015-01-16 |
| PL2154967T3 (pl) | 2014-08-29 |
| TW200848049A (en) | 2008-12-16 |
| DK2154967T5 (en) | 2014-11-17 |
| PT2154967E (pt) | 2014-06-05 |
| RU2455994C2 (ru) | 2012-07-20 |
| US20130065890A1 (en) | 2013-03-14 |
| ES2465673T3 (es) | 2014-06-06 |
| NZ580671A (en) | 2012-03-30 |
| US8349859B2 (en) | 2013-01-08 |
| KR101424847B1 (ko) | 2016-07-08 |
| KR20100016592A (ko) | 2010-02-12 |
| SI2154967T1 (sl) | 2014-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0809715A2 (pt) | "composto, método de tratamento de um distúrbio relacionado com a angiogênese,método de inibição da atividade de receptor de domínio de inserto de quinase, método de inibição de angiogênese e método de tratamento de degeneração macular" | |
| GB0309009D0 (en) | Quinazoline derivatives | |
| MX2009004426A (es) | Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met. | |
| TW200720268A (en) | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | |
| WO2007087245A3 (en) | Ret tyrosine kinase inhibition | |
| BRPI0713555A2 (pt) | ciclopenta [d] pirimidinas como inibidores de akt protéina cinase | |
| NO20083923L (no) | Pyrazolkinoloner er potente parp-inhibitorer | |
| UA100846C2 (uk) | Сполуки та композиція як інгібітори протеїнкінази | |
| EA200900798A1 (ru) | Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы | |
| BRPI0710521A2 (pt) | quinazolinas para inibição de pdk1 | |
| BRPI0714665A2 (pt) | Composto, pró-droga, agente farmacêutico, e, método para a profilaxia ou tratamento do câncer | |
| TN2011000220A1 (en) | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors | |
| MX2009007075A (es) | Metodos de uso para analogos de ciclopamina. | |
| MX2007015863A (es) | Inhibidores de esfingosina cinasa. | |
| NO20061320L (no) | Kinazolinderivater som antitumor agenter | |
| WO2009126514A8 (en) | Compounds and compositions as kinase inhibitors | |
| WO2007142905A3 (en) | 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands | |
| MX2010002899A (es) | Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3. | |
| MX2009008386A (es) | Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pirimidina como inhibidores de proteinas de choque termico-90 para tratar cancer. | |
| MX2010002760A (es) | Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3. | |
| TW200736229A (en) | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | |
| ATE435223T1 (de) | Pyrimidin-, chinazolin-, pteridin- und triazinderivate | |
| ECSP099046A (es) | Derivados ciclopropil amina | |
| EA200870454A1 (ru) | Способ ингибирования c-kit киназы | |
| ATE438641T1 (de) | Chinazolinderivate als inhibitoren von egf und/oder erbb2-rezeptortyrosinkinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A01N 43/54 , C07D 239/42 Ipc: C07D 403/14 (2006.01), C07D 401/14 (2006.01), C07D |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |